ReviewPharmaceutics2023

Business Risk Mitigation in the Development Process of New Monoclonal Antibody Drug Conjugates for Cancer Treatment.

Balázs Kiss et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.